Slide 1: Interim Report Q2 2026 Earnings Call
INTERIM REPORT Q2 2026 EARNINGS CALL 2026-08-19 – WEDNESDAY, AUGUST 19, 2026
Slide 2: Disclaimer
DISCLAIMER You must read the following before continuing. The fol- for publication, release or distribution in the United affect the extent to which a particular projection is real- lowing applies to this document and the information pro- States, the United Kingdom, Australia, Canada or Japan, ised.
Slide 3: Anders Fogelberg, President and CEO of BICO Group from September 1, 2026
Anders Fogelberg, President and CEO of BICO Group from September 1, 2026 25+ years of global industry experience from management positions such as a Managing Director for the SKF Group in Malaysia and Indonesia CEO for med tech company Bellman & Symfon and Chief Marketing Officer and Head of Sales f
Slide 4: Earnings Call Agenda
Earnings Call Agenda Summary Q2 2026 Group Financial Performance Continuous Product Innovation Concluding Remarks Maria Forss Ewa Linsäter President & CEO CFO Q&A 4
Slide 5: Q2 2026 Improved Profitability and AI Advancements
Q2 2026 I Improved Profitability and AI Advancements 336 7 20 -53 NET SALES ORGANIC SALES ADJUSTED OPERATING CASH SEKm GROWTH EBITDA FLOW % SEKm SEKm Q2 2025 – Q2 2026 Net sales and adjusted EBITDA margin Sales (SEKm) Adjusted EBITDA margin (%) 500 15 450 10 400 350 5 300 0 250 -5 200 150 -10 100 -1
Slide 6: BICO's current strengths and technologies are largely grouped into three fields
BICO’s current strengths and technologies are largely grouped into three fields BICO’s current strengths and technologies are largely grouped into three fields Molecular biology Drug Discovery Bioprocessing Next Generation Assay Development Single-cell Proteomics Sequencing Cell Line Development (CL
Slide 7: The Global Challenge
The Global Challenge Long and costly clinical stages combined with low success rate comprise a global challenge for the drug development industry Drug discovery Product development Process development Production > USD 2bn ~ 10% > 10 years Probability of approval Development costs Discovery to approv
Slide 8: Converting AI hypotheses into proven experimental evidence
converting AI hypotheses into proven experimental evidence 02 THE CRITICAL LAYER 01 03 AI Hypothesis Generation AI-Powered Wet Lab Validated Evidence Generative models and predictive Automation Reproducible, compliant, biology produce candidates at scale-ready results that de-risk exponential speed.
Slide 9: BICO Leads the way in Solving the Challenges in Life Science
BICO Leads the way in Solving the Challenges in Life Science with Speed, Accuracy, and Efficiency • Reducing the time to find optimal candidates for treatment Speed therapies • Driving forward a personalized approach in treatment • Enabling the development of physiologically relevant models Accuracy
Slide 10: Summary Q2 2026
Summary Q2 2026 10
Slide 11: Summary Q2 2026
Summary I Q2 2026 CASH FLOW FROM NET SALES ADJUSTED EBITDA OPERATING ACTIVITIES SEK 336m SEK 20m SEK -53m ORGANIC SALES ADJUSTED NWC/LTM SALES GROWTH EBITDA MARGIN 7% 6% 10% All numbers in this presentation refer to continuing operations unless otherwise stated. MatTek and Visikol have been classifi
Slide 12: Group Financial Performance
Group Financial Performance 12
Slide 13: Sales Development (SEKm)
Sales Development (SEKm) SEKm • Gradual market recovery 1,800 1,600 • Sales SEK 336m, an organic growth of 7% 1,400 1,200 • Strong bench top instrument and consumables sales 1,000 800 • Growth YoY in Europe and Asia 600 • Longer lead times for larger 400 automation investments 200 • Improved gross p
Slide 14: Adjusted EBITDA (SEKm) and Margin (%)
Adjusted EBITDA (SEKm) and Margin (%) SEKm % 80 30 56 25 • Adjusted EBITDA SEK 20m 60 20 • Adjusted EBITDA margin 6% 40 15 • Improvement of adjusted 13% 20 EBITDA margin of 17 10 20 21 percentage points 6% 5 5% • Commercial and operational 0 0 excellence activities drives -3% improved profitability
Slide 15: Cash Flow and Financial Position
Cash Flow and Financial Position • Cash flow from operating activities, SEK -53m • includes impact from changes in working capital of SEK -54m • Cash reserves by end of the quarter SEK 628m 15
Slide 16: Development in Net Working Capital between Q2 2025 and Q2 2026
Development in Net Working Capital between Q2 2025 and Q2 2026* SEKm 800 30.0% 600 20.0% 400 12.5% 12.6% 10.9% WC Liabilities 10.4% 10.0% 200 195 188 Other Receivables 169 7.3% 156 109 Accounts Receivables Inventories 0 0.0% Total NWC NWC / LTM Sales -200 -10.0% -400 -600 -20.0% Q2 25 Q3 25 Q4 25 Q1
Slide 17: Continuous Product Innovation
Continuous Product Innovation 17
Slide 18: R&D Pipeline & Roadmap
Instrument Software R&D Pipeline & Roadmap Consumable Product Portfolio 2026 2027 2028 2029 Lab Automation Software Standardized Lab Automation Lab Automation Components Bioprinting Precision Dispenser Liquid Handling Single-cell Dispenser Live-cell Imaging Microscopes 18
Slide 19: AI-Powered Confluency on Rebel & Revolve
AI-Powered Confluency on Rebel & Revolve AFTER ANALYSIS — BEFORE ANALYSIS AI OVERLAY ECHO's new Confluency AI turns one of cell culture's most subjective steps into a quantitative reproducible metric — delivered as a licensed software feature to Rebel and Revolve systems already in the field. Place
Slide 20: Tipless DNA Cleanup on the G.PURE GEN
Tipless DNA Cleanup on the G.PURE GEN 2 G.PURE GEN 2 replaces tip-based magnetic bead cleanup with centrifugal liquid evacuation — removing the consumable from the workflow entirely and collapsing a 20-minute plate cleanup into 2 minutes. 576 → 0 tips 10x faster per 96-well plate — about 300,000 Tim
Slide 21: Thank you!
Thank you! Maria Forss, President and CEO until August 31, 2026, and transition into a senior advisory role to support seamless handover until November 30, 2026. 21 2026-08-19 21
Slide 22: Q&A
Q&A 22 22
Slide 23: Contact Financial Calendar
Contact MARIA FORSS, CEO AND PRESIDENT EWA LINSÄTER, CFO BICO GROUP AB BICO GROUP AB Phone: EA Elisabeth Lindell, +46 761 73 40 59 Phone: +46 766 33 32 33 E-mail: mf@bico.com E-mail: ewa.linsater@bico.com BICO leverages a global portfolio of pioneering brands fusing automation, intelligence, and dat
Slide 24: 2026-08-19
2026-08-19